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SIGNIFICANCE STATEMENT
After 17 years of extensive debate and discussion, mitochondrial donation may now, for the
first time, give some women with mitochondrial DNA disease the opportunity to have a
healthy child that is genetically related to both parents.
Mitochondrial DNA disorders are a group of
common genetic diseases which affect both chil-
dren and adults. They lead to progressive multi-
system disease for which there is no curative
treatment. Inherited mitochondrial DNA muta-
tions are transmitted maternally, and preventing
transmission of these diseases is a priority for
families. An important new approach is a novel
in vitro fertilisation (IVF) technique called mito-
chondrial donation using either maternal spin-
dle transfer or pronuclear transfer [1]. The 4th
March 2015 saw an historic event—the legisla-
tion was put in place to make mitochondrial
donation legal in the UK. Critics of the technique
have claimed that the new law was rushed
through and that there had been insufficient
time to debate the issues. Here we provide a
brief account of the past 17 years to show that
this is not the case.
The complete human mitochondrial
genome, made up of only 16,569 base pairs,
was first sequenced in 1981 [2]. Around the
same time, in an entirely unrelated area of
research, the technique of nuclear transplanta-
tion between mouse embryos was described [3,
4]. The first human pathogenic mitochondrial
DNA mutations were identified in 1988 [5, 6]
and by 1995, the possibility of preventing the
transmission of mitochondrial DNA disease by
nuclear transplantation was already being con-
sidered [7]. Since then, although the name for
the technique we now know as mitochondrial
donation has changed several times, the scien-
tific, ethical, and legal issues have been exam-
ined in detail by a number of independent
groups and committees over many years.
The need to regulate the use of human
embryos in both fertility treatment and scien-
tific research was recognized in the UK follow-
ing the birth of the first IVF baby in 1978. This
major breakthrough led to concerns about the
social and legal implications of such advances
in human assisted reproduction. To address
these issues, the Government established the
Committee of Inquiry into Human Fertilisation
and Embryology chaired by the now Baroness
Mary Warnock. The report [8], published in
1984, set out a blue-print for the regulation of
both IVF and embryo research, and with admi-
rable foresight, included a chapter describing
possible future developments in embryo
research. This report was followed by the
White Paper “Human Fertilisation and Embry-
ology: A Framework for Legislation” which was
published in 1987 and formed the basis for
the Human Fertilisation and Embryology Act
1990 (“the 1990 Act”) [9].
There were rapid and significant advances in
non-human embryo research over subsequent
years, including somatic cell nuclear transfer and
the birth of Dolly the sheep in 1996 [10]. These
developments generated much public interest
and highlighted the need for a clarification of the
legislation regarding the implications for human
clinical embryology. A report by the Human Fer-
tilisation and Embryology Authority (HFEA) and
Human Genetics Advisory Commission (HGAC)
[11], published in 1998, acknowledged that some
of the scientific possibilities being discussed at
this time had not been envisaged when the 1990
Act was drafted. Specifically, the Report recom-
mended that the purposes for which human
embryos could be used in research should be
extended to allow the development of methods
of therapy for mitochondrial diseases.
Following this Report, the Government
established an expert group chaired by the Chief
Medical Officer (Professor Sir Liam Donaldson)
to examine the potential benefits of a number
of new areas of human embryo research, includ-
ing methods to prevent mitochondrial disease.
The report [12] made several recommendations
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including research to increase the understanding of, and
develop treatments for, mitochondrial disease.
The Human Fertilisation and Embryology (Research Pur-
poses) Regulations 2001 followed [13], which extended the
purposes for which research on early human embryos could
be undertaken. A Select Committee on Stem Cell Research
was appointed to consider the issues arising from these regu-
lations. The report [14], published in 2002, stated that the
methods to prevent mitochondrial disease could have “great
potential” and that there was a “strong scientific and medical
case for further research.”
In May 2004, our team at Newcastle University applied
for a research licence from the HFEA to conduct research into
using pronuclear transfer to avoid the transmission of mito-
chondrial disease. After extensive review of both the scientific
methodology and the legal implications of this proposal by
the HFEA, the team was granted a licence in September 2005.
In 2008, thorough revisions to the 1990 Act were passed
by a significant majority in both Houses of Parliament follow-
ing nearly 2 years of debate. This included a specific provision
to allow for regulations to be passed in the future by Parlia-
ment to permit the clinical application of “techniques that
alter the DNA of an egg or embryo to prevent the transmis-
sion of serious mitochondrial disease” (section 3ZA(5)) [15].
In May 2010, the HFEA’s Scientific and Clinical Advances
Advisory Committee (“SCAAC”) considered the potential use
of mitochondrial donation to avoid the transmission of mito-
chondrial disease. It was then in November 2010 that the
Government was invited to consider exercising the regulation-
making power added to the 1990 Act in order to make it pos-
sible for mitochondrial donation to be used as a clinical treat-
ment. Following this request, in February 2011 the Secretary
of State for Health asked the HFEA to scope “expert views on
the effectiveness and safety of mitochondrial transfer.” The
HFEA established an independent panel to collate and sum-
marize scientific evidence from a wide range of experts in the
field. The panel published its first report in April 2011 [16]
and subsequently met and published two further reports in
March 2013 [17] and June 2014 [18].
Many important scientific developments were considered
by the panel in these reports, including that maternal spindle
transfer between non-human primate oocytes resulted in the
birth of healthy offspring with the capacity to prevent mito-
chondrial DNA disease [19]. Data published by our group
demonstrated that pronuclear transfer between human
embryos was feasible and had the potential to prevent mito-
chondrial DNA disease [20]. Further experiments performed
using human oocytes confirmed that maternal spindle transfer
had the potential to prevent mitochondrial DNA disease [21,
22] but required further optimization to improve the effi-
ciency of the technique. Following careful consideration of
the data provided by these studies, and many others, the
panel reached the same conclusion following each report that
there was no evidence to suggest that the technique of mito-
chondrial donation was unsafe for clinical use.
The ethical concerns about using this technology in
humans were debated widely. An independent public consul-
tation and review by the Nuffield Council on Bioethics consid-
ered the implications of the proposed techniques. Their
report [23] was published in June 2012 and supported the
clinical use of mitochondrial donation.
The HFEA were also asked to seek public views on mito-
chondrial donation and a public dialogue launched in collabora-
tion with Sciencewise in December 2012 [24]. The consultation
was thoroughly evaluated and credited as an exemplary exercise
in public engagement for policy purposes [25]. The HFEA pub-
lished its report of the consultation in March 2013 [26] and its
advice to Government was that there was general support for
permitting mitochondrial donation in the UK. It was also
reported that the ethical concerns were outweighed by the
arguments in favor of permitting mitochondrial donation.
In June 2013, following the collective outcomes of the sci-
entific reviews, the public consultation and the report of the
Nuffield Council on Bioethics, the UK Government announced
their decision to publish draft regulations to amend the 1990
Act to permit the clinical application of mitochondrial dona-
tion. The draft regulations were published in February 2014
and a further public consultation launched [27]. Following
careful consideration of the responses to this consultation,
regulations were laid before Parliament in December 2014.
On 3 February 2015, there was a debate and vote in the
House of Commons to decide whether to approve the draft
Regulations to allow mitochondrial donation. The House of
Commons voted by 382 to 128 in support of the Regulations.
Three weeks later, on 24 February 2015, the House of Lords
debated the draft Regulations and voted by 280 to 48 in
support, allowing the Regulations to become law.
On 4 March 2015, the Parliamentary Under-Secretary of
State for Public Health at the Department of Health (Jane Elli-
son MP) signed the Mitochondrial Donation Regulations [28],
making mitochondrial donation legal for the first time in the
UK. The HFEA will now develop a licensing framework through
which applications can be considered on a case by case basis.
After 17 years of extensive debate and discussion, mitochon-
drial donation may now, for the first time, give some women
with mitochondrial DNA disease the opportunity to have a
healthy child that is genetically related to both parents. While
the UK is the first to legislate in this area, there is likely to be
interest from other countries in mitochondrial donation. For
example, the US Food and Drug Administration has requested
that the Institute of Medicine produce a consensus report
into the ethical and social policy considerations of novel tech-
niques for prevention of maternal transmission of mitochon-
drial DNA diseases.
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